Evidence map›Paper›PMID 41596216›Full record

ArticleInternational journal of molecular sciences2026

Cyclophosphamide-Mediated Induction of Myeloid-Derived Suppressor Cells In Vivo: Kinetics of Accumulation, Immune Profile, and Immunomodulation by Oleanane-Type Triterpenoids.

Mona S Awad, Aleksandra V Sen'kova, Andrey V Markov, Oksana V Salomatina, Marina A Zenkova, Oleg V Markov

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mona S AwadInstitute of Chemical Biology and Fundamental Medicine SB RAS, Academician Lavrentyev Ave. 8, 630090 Novosibirsk, Russia.ORCID 0009-0008-2075-2599
Aleksandra V Sen'kovaInstitute of Chemical Biology and Fundamental Medicine SB RAS, Academician Lavrentyev Ave. 8, 630090 Novosibirsk, Russia.ORCID 0000-0001-5729-9910
Andrey V MarkovInstitute of Chemical Biology and Fundamental Medicine SB RAS, Academician Lavrentyev Ave. 8, 630090 Novosibirsk, Russia.ORCID 0000-0001-7569-9555
Oksana V SalomatinaN.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS, Academician Lavrentyev Ave., 9, 630090 Novosibirsk, Russia.ORCID 0000-0002-5316-790X
Marina A ZenkovaInstitute of Chemical Biology and Fundamental Medicine SB RAS, Academician Lavrentyev Ave. 8, 630090 Novosibirsk, Russia.ORCID 0000-0003-4044-1049
Oleg V MarkovInstitute of Chemical Biology and Fundamental Medicine SB RAS, Academician Lavrentyev Ave. 8, 630090 Novosibirsk, Russia.ORCID 0000-0002-8381-1890

Funding

Russian Science Foundation 19-74-30011Russian state-funded project for ICBFM SB RAS 125012300659-6
6 · The paper itself

Abstract

Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells that strongly suppress immunity and expand during tumor progression. Various antitumor chemotherapy agents can induce MDSC accumulation, reducing treatment effectiveness. We investigated the impact of the CHOP regimen and its components (cyclophosphamide (CTX), doxorubicin, vincristine, and prednisolone) on the dynamics of MDSC accumulation and the associated changes in immune cell profiles in the peripheral blood and spleen of healthy and lymphosarcoma RLS

Indexed as

CyclophosphamideImmunomodulationMyeloid-Derived Suppressor CellsOleanolic AcidAnimalsDoxorubicinKineticsMaleMiceMice, Inbred CBASpleenT-LymphocytesVincristineCyclophosphamideDoxorubicinOleanolic AcidVincristinechemotherapyCHOPcyclophosphamideimmunosuppressionMDSCsmyeloid-derived suppressor cellstriterpenoidstumor

Identifiers

PMID41596216
PMCPMC12840754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.